Natera, Inc. (NASDAQ:NTRA) Shares Sold by Fmr LLC

FMR LLC cut its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 60.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,476,022 shares of the medical research company's stock after selling 2,265,757 shares during the period. FMR LLC owned about 1.12% of Natera worth $233,654,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in NTRA. Blue Trust Inc. lifted its holdings in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after acquiring an additional 97 shares in the last quarter. Versant Capital Management Inc boosted its holdings in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after buying an additional 166 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after purchasing an additional 261 shares in the last quarter. Principal Securities Inc. raised its holdings in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after purchasing an additional 59 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its position in Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after buying an additional 332 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Robert W. Baird raised their target price on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. Royal Bank of Canada assumed coverage on Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price objective for the company. The Goldman Sachs Group boosted their target price on shares of Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Piper Sandler raised their price objective on Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. Finally, Sanford C. Bernstein raised their target price on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research report on Friday, January 10th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $175.76.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 78,553 shares of the firm's stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the transaction, the chief executive officer now owns 267,629 shares of the company's stock, valued at $44,150,756.13. This trade represents a 22.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John Fesko sold 663 shares of the stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the sale, the insider now directly owns 156,044 shares in the company, valued at $27,739,941.88. This trade represents a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 325,922 shares of company stock worth $51,603,664. 7.60% of the stock is currently owned by company insiders.

Natera Stock Performance

NTRA traded down $1.63 during midday trading on Wednesday, hitting $150.11. 480,156 shares of the company traded hands, compared to its average volume of 1,389,901. The firm has a market capitalization of $20.29 billion, a PE ratio of -85.29 and a beta of 1.80. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company's 50-day moving average is $151.62 and its 200 day moving average is $152.40. Natera, Inc. has a 52 week low of $83.13 and a 52 week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $476.10 million for the quarter, compared to analysts' expectations of $447.91 million. On average, research analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.